Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

  • Starting March 23, updated visitor restrictions are in place at Duke Health. No visitors will be allowed into our hospitals until further notice with some limited exceptions. Outpatient restrictions have not changed. Learn More

  • Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Learn More

Antibiotic-Resistant Bacterial infections in Babies - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if a single dose of an antibiotic called dalbavancin is safe and effective to treat infections in children.
What is the Condition Being Studied?
Antibiotic-Resistant Bacterial infections in babies

Who Can Participate in the Study?

To be in this study, your child must:
- Be a preterm baby (32-37 weeks gestation)
- Be term baby (more than 37 weeks gestation) to 28 days old
- Be a young infant (age 28 days to 3 months old)
- Be getting an antibiotic for a bacterial infection for at least 24 hours

Age Group
Children

What is Involved?

If you decide that you would like for your child to be in this study, your child:
- Will be part of this study for about 28 to 35 days
- Will receive a study medicine called Dalbavancin
- Have a physical exam, vital signs, and hearing test
- Will give blood samples

Study Details

Full Title
Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months with Suspected or Confirmed Bacterial Infection
Principal Investigator
KevinWatt
Protocol Number
IRB: PRO00069483
NCT: NCT02688790
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698